[1]. CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises: Case 40011. N Engl J Med, 1954. 250(1): p. 26-30.
[2]. CASTLEMAN, B., L. IVERSON and V.P. MENENDEZ, Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer, 1956. 9(4): p. 822-30.
[3]. Herrada, J., et al., The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med, 1998. 128(8): p. 657-62.
[4]. Dong, Y., et al., Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol, 2015. 169(6): p. 834-42.
[5]. Abramson, J.S., Diagnosis and Management of Castleman Disease. J Natl Compr Canc Netw, 2019. 17(11.5): p. 1417-1419.
[6]. Keller, A.R., L. Hochholzer and B. Castleman, Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer, 1972. 29(3): p. 670-83.
[7]. Cronin, D.M. and R.A. Warnke, Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol, 2009. 16(4): p. 236-46.
[8]. Newman, S.K., et al., Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research. Yale J Biol Med, 2015. 88(4): p. 383-8.
[9]. van Rhee, F., et al., International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018. 132(20): p. 2115-2124.
[10]. Hengge, U.R., et al., Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis, 2002. 2(6): p. 344-52.
[11]. Hengge, U.R., et al., Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis, 2002. 2(6): p. 344-52.
[12]. Szalat, R. and N.C. Munshi, Diagnosis of Castleman Disease. Hematol Oncol Clin North Am, 2018. 32(1): p. 53-64.
[13]. Dossier, A., et al., Human herpesvirus 8-related Castleman disease in the absence of HIV infection. Clin Infect Dis, 2013. 56(6): p. 833-42.
[14]. Liu, A.Y., et al., Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol, 2016. 3(4): p. e163-75.
[15]. Yu, L., et al., Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood, 2017. 129(12): p. 1658-1668.
[16]. Talat, N. and K.M. Schulte, Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist, 2011. 16(9): p. 1316-24.
[17]. Keller, A.R., L. Hochholzer and B. Castleman, Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer, 1972. 29(3): p. 670-83.
[18]. Cronin, D.M. and R.A. Warnke, Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol, 2009. 16(4): p. 236-46.
[19]. Fajgenbaum, D.C., et al., International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood, 2017. 129(12): p. 1646-1657.
[20]. Anhalt, G.J., et al., Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med, 1990. 323(25): p. 1729-35.
[21]. Kaplan, I., et al., Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol, 2004. 40(6): p. 553-62.
[22]. Lehman, V.T., et al., Diagnostic imaging in paraneoplastic autoimmune multiorgan syndrome: retrospective single site study and literature review of 225 patients. Int J Dermatol, 2015. 54(4): p. 424-37.
[23]. Leger, S., et al., Prognostic factors of paraneoplastic pemphigus. Arch Dermatol, 2012. 148(10): p. 1165-72.
[24]. Anhalt, G.J., Paraneoplastic pemphigus. J Investig Dermatol Symp Proc, 2004. 9(1): p. 29-33.
[25]. Frew, J.W. and D.F. Murrell, Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin, 2011. 29(4): p. 607-12.
[26]. Shin, D.Y., et al., Clinical dissection of multicentric Castleman disease. Leuk Lymphoma, 2011. 52(8): p. 1517-22.
[27]. Zhang, X., et al., Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. Cancer Sci, 2018. 109(1): p. 199-206.
[28]. Talat, N., A.P. Belgaumkar and K.M. Schulte, Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg, 2012. 255(4): p. 677-84.
[29]. Lee, J.H., et al., Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. Leuk Res, 2010. 34(1): p. e42-5.
[30]. Gerard, L., et al., Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol, 2007. 25(22): p. 3350-6.
[31]. Bower, M., et al., Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med, 2007. 147(12): p. 836-9.
[32]. Nishimoto, N., et al., Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 2005. 106(8): p. 2627-32.
[33]. Turcotte, L.M., et al., Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr Blood Cancer, 2014. 61(4): p. 737-9.
[34]. Cai, S., et al., Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report. Medicine (Baltimore), 2019. 98(46): p. e17681.